• Sourcews Report
  • File
  • HTML
  • Size
  • 49 Ko
  • URL response
  • 100%
  • Source quality
  • 76%
  • Sourcews Explorer
ACZ885 Phase III data show rapid, sustained clinical remission in children and adults suffering from a group of rare, potentially life-threatening autoinflammatory diseases
27.10.08 - 11:34 ... source : Novartis
... Patients with rare autoinflammatory syndromes achieved remission after a single ACZ885 dose - treatment needed only every two months to maintain response[1] ACZ885 demonstrated potential to rapidly control Systemic Juvenile Idiopathic Arthritis, the most severe form of arthritis in children[2] Orphan drug status granted to ACZ885 in the EU and US, filing on track in the EU and US Studies of ACZ885 currently under way in rheumatoid arthritis and gout using an innovative tailored approach with biomarkers Basel, October 27, 2008 - New Phase III data demonstrate that ACZ885 (canakinumab), a biological drug in development, achieved rapid and long-lasting clinical remission after just one dose in children and adults with a group of rare but potentially life-threatening autoinflammatory diseases called Cryopyrin ...» Next (HTML)
Similar news
90% | 08.10.08 - 15:59 ... source : Novartis
...  clinical improvement in patients with pulmonary arterial hypertension (PAH) Current treatment options have limited benefit for this debilitating, rapidly progressive and incurable blood vessel disease Imatinib, available as Glivec® for treatment of certain cancers, known ...
Health »    
89% | 07.10.08 - 21:38 ... source : Novartis
...  and potentially faster onset of action[1] Data show NVA237 was well tolerated with good overall safety profile and no clinically relevant cardiovascular findings[2] Chronic obstructive pulmonary disease (COPD) affects 210 million people worldwide[3] - projected ...
89% | 25.09.08 - 10:42 ... source : Sepracor
...  eslicarbazepine acetate in more than 1,000 patients with refractory partial epilepsy -- Studies demonstrated marked and sustained seizure reduction and significant improvement in quality of life and depressive symptoms over a one-year treatment period -- ...
88% | 26.10.08 - 19:52 ... source : Schering-Plough
...  Data Analysis of Up to Four Years of Treatment Presented at ICAAC/IDSA 2008 Annual Meeting Schering-Plough Corporation (NYSE: SGP) today reported a data analysis showing that vicriviroc, its investigational CCR5 receptor antagonist, demonstrated sustained viral ...
Health »    
Topics in alphabetical order : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z